ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1942 • ACR Convergence 2021

    Occurrence of Basal Cell and Squamous Cell Carcinomas of the Skin Under Different DMARD Therapies

    Imke Redeker1, Peter Herzer2, Cornelia Kühne3, Ilka Schwarze4, Martin Schaefer5 and Anja Strangfeld6, 1German Rheumatism Research Centre (DRFZ), Berlin, Germany, 2Scientific Advisory Board, Munich, Germany, 3Rheumatologist, Haldensleben, Germany, 4Rheumatologist, Leipzig, Germany, 5German Rheumatism Research Center, Berlin, Germany, 6Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany

    Background/Purpose: Squamous and basal cell carcinomas are the most common malignancies of the skin; they are subsumed under non-melanoma skin cancer (NMSC). The risk of…
  • Abstract Number: 1939 • ACR Convergence 2021

    Risk of Cardiovascular Outcomes in Patients Treated with Tofacitinib: First Results from the Safety of TofAcitinib in Routine Care Patients with Rheumatoid Arthritis (STAR-RA) Study

    Farzin Khosrow-Khavar, Seoyoung Kim, Hemin Lee, Su Been Lee and Rishi Desai, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Recent reports from a post-marketing safety trial, “ORAL Surveillance”, indicated an increased risk of cardiovascular (CV) outcomes in RA patients treated with tofacitinib. Thus,…
  • Abstract Number: 1921 • ACR Convergence 2021

    Axial Psoriatic Arthritis: Correlation Between Whole Spine MRI Abnormalities and Clinical Findings

    Pamela Diaz1, Iris Eshed2, Joy Feld3 and Lihi Eder1, 1University of Toronto, Toronto, ON, Canada, 2Sheba Medical Center, Ramat Gan, Israel, 3Carmel and Zvulun Medical Centre, Haifa, Israel

    Background/Purpose: Psoriatic Arthritis (PsA) typically affects peripheral joints, but in some patients the disease can involve the spine. While magnetic resonance imaging (MRI) is an…
  • Abstract Number: 1900 • ACR Convergence 2021

    Urate Lowering Therapy in the Treatment of Gout: A Multicenter, Randomized, Double-blind Comparison of Allopurinol and Febuxostat Using a Treat-to-Target Strategy

    James O'Dell1, Tuhina Neogi2, Michael Pillinger3, Paul Palevsky4, Jeff Newcomb1, Mary Brophy5, Hongsheng Wu5, Annie Davis-Karim6, Ryan Ferguson5, David Pittman6, Robert Terkeltaub7, Amy Cannella1, Bryant England1, Lindsay Helget1, Ted Mikuls1 and Tomas Taylor8, 1University of Nebraska Medical Center, Omaha, NE, 2Boston University School of Medicine, Boston, MA, 3New York University Grossman School of Medicine, New York,, NY, 4Pittsburgh University, Pittsburgh, PA, 5Boston VA, Boston, MA, 6Albuquerque VA, Albuquerque, NM, 7VA/UCSD, San Diego, CA, 8White River Junction VA, White River Junction, VT

    Background/Purpose: Urate lowering therapy (ULT) is a cornerstone treatment in the management of gout. A paucity of data exists about the relative efficacy and safety…
  • Abstract Number: PP04 • ACR Convergence 2021

    Dual Roles: Thriving with SLE as a Medical Student

    Chieh Lo1 and Song-Chou Hsieh2, 1School of Medicine, I-Shou Univerity, Kaohsiung, Taiwan (Republic of China), 2Division of Immunology, Allergy and Rheumatology, Department of Medicine, National Taiwan University Hospital, Taipei, Taiwan (Republic of China)

    Background/Purpose: A few days after my 18th birthday, I walked into a rheumatology clinic for the first time. I had ulcers in my mouth, felt…
  • Abstract Number: PP02 • ACR Convergence 2021

    Leveraging Digital Health Tracking to Improve Arthritis Management

    Katie Roberts, Annapolis, MD

    Background/Purpose: I was diagnosed with psoriasis when I was age 10 in 1986. At that time, my treatment plan consisted of regular application of Eucerin…
  • Abstract Number: PP07 • ACR Convergence 2021

    How Online Spanish-Language Resources Got Me and My RA Through the COVID-19 Pandemic

    Wigna Cruz, Puerto Rico

    Background/Purpose: I was experiencing joint pain especially in my wrists, which led me to see my physician for testing. Initially I was misdiagnosed with lupus.…
  • Abstract Number: PP06 • ACR Convergence 2021

    Collaborative Advocacy Helps Me and Other Patients With Relapsing Polychondritis (“RP”’) /  My life improved by helping the RP Foundation and Race for RP facilitate awareness, education, and research to improve the quality of life for patients with RP and advance a cure for this disease.

    Michael Linn1 and Dan Smith2, 1Relapsing Polychondritis Foundation, New York, NY, 2Relapsing Polychondritis Foundation, Canton, MI

    Background/Purpose: In March 2020, I was diagnosed as having relapsing polychondritis ("RP"), an understudied, underdiagnosed, and undertreated debilitating autoimmune disease that can be fatal if…
  • Abstract Number: PP09 • ACR Convergence 2021

    Family Planning while Living with Rheumatoid Arthritis

    Shannan O'Hara-Levi, Monroe, NY

    Background/Purpose: Over the course of my 30+ years living with Polyarticular Juvenile Rheumatoid Arthritis, I have never had long term success on any one biologic treatment,…
  • Abstract Number: PP10 • ACR Convergence 2021

    Discovering ‘I’ Through Interaction with Support Group Members: A Place of Empathy That Transcends the Limitations of Words

    Noriko Okochi1, Eiji Oishi2 and Mika Ishiguro1, 1Rheumatic Disease and Vasculitis Support Network Japan, Tokyo, Japan, 2Rheumatic Disease and Vasculitis Support Network Japan, Yamaguchi, Japan

    Background/Purpose: Since 5-year-old, I have had unexplained symptoms. At the age of 13, my whole body became inflamed. The pain was so intense that I…
  • Abstract Number: PP01 • ACR Convergence 2021

    Unicycling for a Cure: My UNIque Physical Activity Intervention for Rheumatoid Arthritis During the COVID19 Pandemic

    Dana Guglielmo, San Diego, CA

    Background/Purpose: I was diagnosed with rheumatoid arthritis at age 17. In my 20s, I joined Racing For A Cure of the Arthritis National Research Foundation,…
  • Abstract Number: PP12 • ACR Convergence 2021

    Fighting for the Care We Deserve: My Experience as a Latina Patient-Researcher During the COVID-19 Pandemic

    Guadalupe Torres1, Courtney Wells2 and Kristine Carandang3, 1, 2University of Wisconsin-River Falls, School of Social Work, St. Paul, MN, 3Global Healthy Living Foundation, CreakyJoints, San Diego, CA

    Background/Purpose: I am a 23-year-old first generation Latina with rheumatoid arthritis (RA). Despite being disproportionately affected by rheumatic conditions, the perspectives of Latinx remain poorly…
  • Abstract Number: 1945 • ACR Convergence 2021

    Efficacy of Upadacitinib on Psoriatic Arthritis with Axial Involvement Defined by Investigator Assessment and PRO-Based Criteria: Results from Two Phase 3 Studies

    Xenofon Baraliakos1, Roberto Ranza2, Andrew Ostor3, Francesco Ciccia4, Laura Coates5, Simona Rednic6, Jessica Walsh7, Tianming Gao8, Apinya Lertratanakul8, In-Ho Song8, Fabiana Ganz8, Kevin Douglas8 and Atul Deodhar9, 1Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, 2Hospital de Clinicas, Universidade Federal de Uberlândia, Uberlandia, MG, Brazil, 3Monash University, Cabrini Hospital, and Emertius Research, Malvern, Australia, 4University of Campania Luigi Vanvitelli, Napoli, Italy, 5Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 6Emergency Clinical County Hospital, Rheumatology and Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania, 7Salt Lake City Veteran Affairs Medical Center (VAMC)/University of Utah Hospital, Salt Lake City, UT, 8AbbVie Inc., North Chicago, IL, 9Oregon Health & Science University, Portland, OR

    Background/Purpose: Patients with PsA and axial involvement have higher disease activity and greater reductions in quality of life;1 however, there are no accepted criteria for…
  • Abstract Number: 1944 • ACR Convergence 2021

    Sustained Remission/Low Disease Activity Is Feasible in the Long Term in Patients with Psoriatic Arthritis Treated with IL-23/12 Inhibition with Ustekinumab (STELARA®) and Tumor Necrosis Factor Inhibitors in a Real-World, Multicenter Study

    Josef Smolen1, Paul Bergmans2, Kurt de Vlam3, Elisa Gremese4, Beatriz Joven-Ibáñez5, Tatiana Korotaeva6, Wim Noël7, Michael Nurmohamed8, Petros Sfikakis9, Stefan Siebert10, Elke Theander11 and Laure Gossec12, 1Medical University of Vienna, Vienna, Austria, 2Janssen-Cilag BV, Breda, Netherlands, 3University Hospitals Leuven, Leuven, Belgium, 4Fondazione Policlinico A Gemelli-IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy, 5University Hospital 12 de Octubre, Madrid, Spain, 6VA Nasonova Research Institute of Rheumatology, Moscow, Russia, 7Janssen Pharmaceutica, HEMAR Department, Beerse, Belgium, 8Reade and Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands, 9National Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, 10University of Glasgow, Glasgow, United Kingdom, 11Janssen Cilag, Lund, Sweden, 12Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France

    Background/Purpose: Among treatment options for PsA, IL-23/12 inhibition with ustekinumab (UST) was the first new biologic after TNF inhibitors (TNFi). Few data compare long-term effectiveness…
  • Abstract Number: 1803 • ACR Convergence 2021

    Long-term Safety of Guselkumab (TREMFYA®) in Patients with Active Psoriatic Arthritis: Pooled Results from 3 Randomized Clinical Trials Through up to 2 Years

    Proton Rahman1, Christopher Ritchlin2, Philip Mease3, Philip S Helliwell4, Wolf-Henning Boehncke5, Iain McInnes6, May Shawi7, Anne Marilise Marrache8, Alexa Kollmeier9, Xie Xu10, Jenny Yu10, Yanli Wang10, Shihong Sheng10 and Alice Gottlieb11, 1Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, 2Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, 3Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, 4Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 5Geneva University Hospitals, Geneva, Switzerland, 6University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom, 7Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, 8Janssen Inc., Toronto, ON, Canada, 9Janssen Research & Development, LLC, La Jolla, CA, 10Janssen Research & Development, LLC, Spring House, PA, 11Icahn School of Medicine at Mount Sinai, New York, NY

    Background/Purpose: Guselkumab (GUS), a targeted IL-23 inhibitor, demonstrated significant improvements in signs and symptoms of psoriatic arthritis (PsA) and a favorable safety profile through week…
  • « Previous Page
  • 1
  • …
  • 645
  • 646
  • 647
  • 648
  • 649
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology